// App-Quantinova.ai

6645 : Anti-EGF antibodies significantly improve the activity of RET, BRAF, MEK and PI3K kinase inhibitors in preclinical models

Researchers

Presenter

  • Silvia Garcia Roman

Principal Investigators

  • Jordi Codony Servat

  • Miguel Angel Molina Vila

  • Jordi Bertran Alamillo

  • Monica Garzon

  • Alejandro Martnez Bueno

  • Santiago Viteri

  • Mara Gonzlez Cao

  • Andrs Aguilar

  • Juan Jos Garca

  • Erik d'Hondt

  • Rafael Rosell

Medical Centers

  • Pangaea Oncology, Barcelona, Spain

  • Instituto Oncologico Dr. Rosell, Barcelona, Spain

  • Bioven, Aberdeen, United Kingdom.

Locations

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Ret Proto-Oncogene

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved